Learn more about our Advocacy work.
WASHINGTON, D.C. – In a new op-ed in The Washington Times, Scott Whitaker, president and CEO of AdvaMed, the MedTech Association®, laid out medtech’s vital role in the Trump administration’s…
WASHINGTON, D.C.—Scott Whitaker, president and CEO of AdvaMed, the MedTech Association®, issued the following statement on the White House’s “America’s AI Action Plan”:
Discover our Q2 report highlighting key industry wins, tariff updates, and strategic progress driving medtech innovation and advocacy forward.
AdvaMed® submitted public comments in response to HHS’s request for information on eliminating federal regulations that hinder economic growth, innovation, and American competitiveness.
JoinAdvaMed® and Reed Smith experts to explore how the Supreme Court’s ACA ruling in Braidwood could shape preventive care and MedTech policy.
WASHINGTON – Today, AdvaMed, the MedTech Association®, released the following statement from President and CEO Scott Whitaker on the impact the “One Big Beautiful Bill Act” will have on medtech…
AdvaMed’s annual Medtech Showcase and Reception on Capitol Hill seeks to inform a core audience: the members of the Congress and their staff who enact the policies that help our…
AdvaMed® President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly,…
Emergency Briefing on Court Ruling on Tariffs and Its Impact on Medtech. Now On Demand!
WASHINGTON—AdvaMed, the MedTech Association®, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen…